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AbstrACt
Objectives To summarise the definitions and 
combinations of codes used to identify outcomes of 
anxiety, depression, fatigue, cognitive dysfunction 
(including mild cognitive dysfunction and dementia), sexual 
dysfunction, pain, sleep disorders, and fatal and non-fatal 
self-harm in studies using electronic health records from 
primary care databases in the UK.
Design Systematic review.
Data sources Medline, Embase and lists of publications 
of the main primary care databases in the UK.
Eligibility criteria Included data from a UK primary care 
database and studied outcome(s) of interest.
Data extraction and synthesis We abstracted 
information on the outcomes definition and codelists. 
When necessary, authors were contacted to request 
codelists.
results 120 studies were eligible. Codelists were 
available for 17/42 studies of depression; 21/41 studies of 
fatal and non-fatal self-harm; 17/27 studies of dementia/
cognitive dysfunction; 5/12 studies of anxiety; 4/8 studies 
of pain; 3/6 studies of fatigue and sexual dysfunction; 1/2 
studies of sleep disorders. Depression was most often 
defined using codes for diagnoses (37/42 studies) and/or 
antidepressants prescriptions (21/42 studies); six studies 
reported including symptoms in their definition. Anxiety 
was defined with codes for diagnoses (12/12 studies); four 
studies also reported including symptoms. Fatal self-harm 
was ascertained in primary care data linked to the Office 
for National Statistics mortality database in nine studies. 
Most studies of cognitive dysfunction included Alzheimer’s 
disease, and vascular and frontotemporal dementia. 
Fatigue definitions varied little, including chronic fatigue 
syndrome, neurasthenia and postviral fatigue syndrome. 
All studies of sexual dysfunction focused on male 
conditions, principally erectile dysfunction. Sleep disorders 
included insomnia and hypersomnia. There was substantial 
variability in the codelists; validation was carried out 
i21/120 studies.
Conclusions There is a need for standardised definitions 
and validated list of codes to assess mental health and 
quality of life outcomes in primary care databases in the UK.
IntrODuCtIOn
Primary care databases of electronic health 
records (EHRs) in the UK such as The Clin-
ical Practice Research Datalink (CPRD), 
QResearch or The Health Improvement 
Network (THIN) have been widely used to 
study mental health outcomes such as depres-
sion,1 2 and other key aspects of quality of 
life (QoL), such as fatigue and pain,3 4 even 
though the identification of patients with 
these conditions is not straightforward.
Strategies to identify patients with a given 
condition in the EHRs typically include gener-
ating lists of relevant codes, then searching 
the patients’ record for these codes to identify 
symptoms, diagnoses, referrals, appointments 
for disease management and monitoring, 
and/or prescriptions of interest.5 The process 
of developing a list of codes of interest, and 
deciding how to apply them, may be subjec-
tive. For example, a study on the selection of 
codes for stroke, a relatively well-defined clin-
ical outcome, showed that researchers with 
clinical and epidemiological experience may 
have differing interpretations of the relevance 
of each code.6 A systematic review on the iden-
tification of patients with cancer in UK primary 
care databases described several combinations 
of Read codes used across studies.7 Estimates 
of validity of diagnoses in these databases 
have been generally high across disease 
types,8 9 but the heterogeneity in the codelists 
raises issues of misclassification, and hampers 
strengths and limitations of this study
 ► Comprehensive systematic review of the literature 
aiming at describing the definitions and combination 
of codes used to identify outcomes of mental health 
and quality of life in electronic health records data-
bases in the UK.
 ► Potential for error in the selection of the eligible 
studies minimised by duplication of the screening.
 ► The authors of the original studies were contacted to 
obtain the list of Read codes used when these were 
not publicly available.
 ► We only considered definitions of study outcomes, 
and did not consider studies where mental health or 
quality of life variables were covariates or exposure 
variables, limiting the generalisability of our results 
to these other contexts.
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the comparability of studies using the same data to assess 
the same outcome.10 The pattern of use of the codes by 
the general practitioners (GPs) also needs consideration. 
For example, in recording depression, it has been shown 
that GPs have switched from diagnostic to symptom codes 
in recent years11; this may have a large impact on outcome 
definitions based around diagnostic codes. In addition, 
outcome definitions using prescription data may lead to 
misclassification where drugs have multiple indications: for 
example, sertraline, paroxetine or escitalopram, among 
the most commonly used antidepressants, are also first-line 
treatments for generalised anxiety disorder12; and amitrip-
tyline, a tricyclic antidepressant, is also a first-line treatment 
for neuropathic pain.13
Given the broad interest in mental health and QoL 
outcomes, and the strong potential for primary care data 
to contribute to studying these outcomes, our aim was to 
systematically review and summarise the strategies used to 
define such outcomes in previous studies, and the extent 
to which case definitions have been validated.
MEthODs
This review followed the a priori defined methods speci-
fied in the systematic review protocol (online supplemen-
tary appendix 1).
Outcomes of interest
The outcomes of interest for this review were: anxiety, 
depression, fatigue, cognitive dysfunction, pain, sexual 
dysfunction, sleep disorder and fatal and non-fatal self-
harm. We considered that a study provided data for cogni-
tive dysfunction when dementia, mild cognitive impairment 
or single domains of cognitive function were studied (ie, 
attention, executive function, memory, language, motor 
and social). Composite outcomes of two or more of these 
outcomes (eg, psychological impairment defined by anxiety 
or depression) were also eligible.
Information sources and search strategy
We searched MEDLINE and Embase via Ovid, from incep-
tion up to 28 June 2018, to identify studies that involved 
EHRs from primary care databases and studied one of the 
outcomes of interest (see above). The search expressions 
are provided in online supplementary appendix 1, and 
combined terms to identify primary care databases, terms 
to identify mental health and QoL outcomes, and terms 
indicating UK-based research. The CPRD, THIN and 
QResearch list of publications, available in their websites, 
were manually revised to identify additional studies. The 
lists of bibliographical references of the studies consid-
ered eligible for the review were also screened by hand to 
identify additional studies.
studies eligibility
We considered eligible the studies that used data from 
a primary care database that routinely gathers EHR data 
from primary care practices in the UK, and in which the 
outcome of interest was one of those of interest for this 
study (see list above). This included purely descriptive 
studies on the incidence/prevalence of the outcome and 
analytical studies where the condition of interest was one 
of the main outcomes of the study. Studies of primary care 
data linked to other sources of data, such as the Hospital 
Episode Statistics (HES) or the Office for National Statis-
tics (ONS) mortality data, were also considered eligible.
Abstracts from conferences were excluded, as it was 
unlikely that the methods section would provide suffi-
ciently detailed information on the definition of the 
outcomes. Studies of pain caused by infectious agents 
(eg, herpes zoster) were excluded; similarly, studies of 
sleep apnoea and narcolepsy were excluded due to their 
unlikely psychological origin.14 15 Studies reporting only 
on patterns of treatment of the conditions of interest 
were excluded, unless pharmacological treatment was 
clearly used as a proxy for the definition of the condition. 
Studies, where the outcome of interest was comorbidity, 
were also excluded. Where there were multiple studies 
from the same group of authors, we considered these 
separately, since the definition of the same outcomes 
could have been updated over time.
The eligibility of the studies was determined by two 
authors (HC and HS) reviewing all records retrieved from 
the publications databases. First, the title of each study 
was read to determine the eligibility for the review; when 
the information provided in the title was insufficient for a 
clear exclusion of the study, the study was considered for 
further assessment. Second, the full text of each study not 
previously excluded was read, in order to determine the 
eligibility. Disagreements over study eligibility between 
the two reviewers were resolved by discussion, including 
with a third researcher (KB or RW) where needed.
Data acquisition and extraction
We abstracted data on study characteristics (title, study 
design), the primary care database used, any database(s) 
linked to the primary care data, outcome(s) reported, 
definition of the outcome(s) (ie, Read codes, drug 
prescriptions, International Classification of Diseases 
(ICD) codes, etc) and any codelist available. When there 
were two or more definitions of the outcome (eg, used 
in sensitivity analyses), we abstracted all information 
but considered only the main outcome for data analysis 
in this review. We also abstracted data on whether the 
codelist had been validated, and any description related 
to the handling of past or prevalent (at baseline in cohort 
studies) episodes of these outcomes. We considered that 
the study had attempted to validate the list of codes when 
the results were compared with data from another source, 
or when outcomes were confirmed by enquiring the 
patients’ GP or by reviewing the patients’ medical record. 
The data extraction process was repeated by a second 
author (HS) for 10% of the papers included for each 
outcome, to check for reliability in the extraction process.
When a study did not provide the codelist for the 
definition of the outcome in the original publication 
or in a publicly available repository, we contacted the 
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corresponding author of the study by email seeking this 
information (online supplementary appendix 2). In the 
case of emails that could not be delivered to the corre-
sponding author, we searched the contact of another study 
author, usually the first or the last author, and addressed the 
email to her/him; if this failed to be delivered, no further 
attempt of contact was made. For all delivered emails, if no 
response was received within 2 weeks, a follow-up email was 
sent.
Data analysis
We produced descriptive tables showing the number and 
proportion of studies eligible for each outcome, by primary 
care database and codelist availability. We described, for 
each outcome, the types of codes used in the definition 
of the outcomes (eg, diagnosis codes, symptom codes, 
prescription codes). The lists of codes were also reviewed to 
assess the clinical characteristics of the disorders included 
(eg, whether mixed anxiety and depression was included 
in the definition of anxiety or depression); this was done 
by manually reviewing the list of codes to identify codes 
related to different clinical characteristics of the specific 
outcome. To describe the Read codes most commonly used 
to identify these outcomes in the data, we produced a list 
of Read codes sorted by number of studies that used the 
code. The results of the validation studies described in the 
original papers were reported descriptively.
Patient and public involvement
No patients or public were involved in the design and 
conduct of this study.
rEsults
Of 5946 records initially identified in the bibliographical 
references search, 2979 were discarded as being dupli-
cated, which left 2967 records to be assessed for eligibility 
(figure 1). The title assessment resulted in the exclusion 
of 2485 records, and 482 studies were considered for 
full-text assessment. Of these, 368 studies were excluded, 
mostly because they were abstracts from conferences or 
did not evaluate relevant outcomes. Six papers were iden-
tified from the screening of the references. A total of 120 
studies were eligible for the systematic review; a list of 
codes were obtained for nearly half of the studies. The 
definitions and combinations of codes used to identify 
Figure 1 Systematic review flow chart. CPRD, Clinical Practice Research Datalink; THIN, The Health Improvement Network. 
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mental health and QoL outcomes from UK primary care 
databases were heterogeneous for all outcomes; there was 
particular variability in the inclusion/exclusion of codes 
for symptoms of the mental disorders. Prescriptions were 
not frequently used as proxy for mental disorders. Vali-
dation efforts were rarely employed. Detailed results for 
each outcome are provided below.
Anxiety
Twelve studies had anxiety as an outcome (table 1 and 
online supplementary appendix 3 table 1); of these, two 
studied panic only.2 16 The list of codes used to identify 
outcomes of anxiety was available for 5 of the 12 studies 
(41.7%); in one study, the cases of anxiety were identified 
in CPRD data linked to HES. All 12 studies included codes 
for diagnosis of anxiety, and 4 (33.3%) included also codes 
for anxiety symptoms. Prescriptions were considered in the 
definition of the outcome in one study only (8.3%).
Of the five studies for which codelists were available, five 
included codes for generalised anxiety disorder (100%), 
four for phobia (80.0%), four for panic disorder/attacks 
(80.0%), three for mixed anxiety and depression (60.0%), 
and two for stress-related disorders (40.0%) (table 2). 
Codes for post-traumatic stress disorder and obsession-com-
pulsion were less often included (one study each, 20.0%).
Only one study reported including drugs prescriptions 
in the definition of the outcome17; this considered diaz-
epam and lorazepam only (table 3).
Two studies2 18 assessed the validity of the codelists 
(table 4). The proportion of cases confirmed was reported 
in one study: 73.5% for cases treated with anxiolytics, anti-
depressants and hypnotics, and 89.6% in those not phar-
macologically treated.18
Online supplementary appendix 4 table 1 provides the 
list of Read codes used to identify patients with anxiety 
in the eligible studies; online supplementary appendix 4 
table 2 provides the list of ICD-10 codes.
Depression
Forty-two studies identified outcomes of depression 
(table 1 and online supplementary appendix 3 table 2). 
The list of codes used to identify outcomes of depression 
was available for 17 of the 42 studies (40.5%); 2 studies 
identified cases of depression in primary care data linked 
to HES data, using ICD-10 codes. Six studies defined 
depression by proxy of antidepressants intake only; the 
remaining 36 studies described to have included codes 
for diagnoses of depression and 6 (14.3%) studies also 
considered symptoms of depression in the definition of 
the outcome. Fifteen studies (35.7%) reported having 
excluded patients with history of depression.
Of the 17 studies for which the codelists were avail-
able, 10 included codes for mixed anxiety and depression 
(58.8%), 4 for bipolar disorder (23.5%) and 3 for depres-
sion in dementia (17.6%) (table 2).
Antidepressant prescriptions, in isolation or combina-
tion with diagnostic/symptoms Read codes, were consid-
ered in the identification of patients with depression in 
21 studies (50.0%); in six studies, depression was solely 
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defined by the prescription of antidepressants (table 3). 
The list of antidepressant categories was seldom provided; 
of the studies that reported this information, selective 
serotonin reuptake inhibitors were the group most often 
considered (six studies), followed by monoamine oxidase 
inhibitors and tricyclic and related antidepressants drugs 
(three studies each).
Five studies (11.9%) assessed the performance of the 
list of codes to identify patients with depression (table 4). 
The proportion of cases confirmed was reported by two 
studies only: 83.3%19 and 89.6%.20
The list of Read codes used to identify patients with 
depression is provided in online supplementary appendix 
4 tables 3 and  4 provides the list of ICD-10 codes.
Composite outcome of anxiety and depression
Two studies provided data for composite outcomes of 
anxiety and depression (table 1 and online supplemen-
tary appendix 3 table 3). The codelist was available for 
the two studies. The studies reported including codes for 
symptoms as well as diagnosis of anxiety and depression, 
and included prescriptions of antidepressants and anti-
anxiety drugs in the definition of the outcome.
John et al21 compared the performance of 12 different 
algorithms to identify patients with anxiety and depres-
sion in the Secure Anonymised Information Linkage 
Databank; the positive predictive value of the Read codes 
for anxiety and depression diagnoses, symptoms and 
treatments, against the five-item Mental Health Inven-
tory (gold standard), varied between 61% and 76%21 
(table 4). The list of Read codes used to identify patients 
with composite outcomes of anxiety and depression is 
provided in online supplementary appendix 4 table 5.
Cognitive dysfunction (including mild cognitive dysfunction 
and dementia)
Twenty-seven studies reported outcomes of dementia or 
cognitive function (table 1 and online supplementary 
appendix 3 table 4). The codelists were available for 17 
studies (63.0%); in two studies dementia was ascertained 
in primary care data linked to other sources of data. 
All studies included codes for diagnosis of dementia or 
cognitive impairment, and six studies (22.2%) reported 
to have included also codes for symptoms of dementia. 
Twenty-one studies (77.8%) referred to have excluded 
Table 2 Clinical characteristics of the outcomes of interest 
in the studies for which the list of codes was available
Study included codes for N
% of 
total with 
code lists 
available
Anxiety 5 100.0
  Generalised anxiety disorder 5 100.0
  Panic disorder/attacks 4 80.0
  Phobia 4 80.0
  Mixed anxiety and depression 3 60.0
  Stress-related disorders 2 40.0
  Obsession-compulsion 1 20.0
  Post-traumatic stress disorder 1 20.0
Depression 17 100.0
  Unipolar depression 17 100.0
  Depression with psychotic 
symptoms
14 82.4
  Mixed anxiety and depression 10 58.8
  Bipolar disorder 4 23.5
  Depression in dementia 3 17.6
Dementia/cognitive impairment 17 100.0
  Alzheimer’s disease 13 81.3
  Vascular dementia 13 81.3
  Frontotemporal dementia 12 75.0
  Lewy bodies disease 11 68.8
  Mild cognitive impairment only 3 17.6
Fatigue 3 100.0
  Chronic fatigue syndrome/myalgic 
encephalitis
3 100.0
  Neurasthenia 3 100.0
  Post viral fatigue syndrome 3 100.0
  Fibromyalgia 2 66.7
Pain 4 100.0
  Chest pain 1 25.0
  Chronic widespread pain 1 25.0
  Musculoskeletal pain 1 25.0
  Unspecified abdominal pain 1 25.0
Sexual dysfunction (male) 3 100.0
  Erectile dysfunction 3 100.0
  Other male sexual dysfunctions 1 33.3
Sleep disorder 1 100.0
  Insomnia 1 100.0
  Hypersomnia 1 100.0
Fatal and non-fatal self-harm 21 100.0
  Completed suicide 17 80.9
  Completed suicide only 8 38.1
  Completed and attempted suicide 
only
6 28.6
Continued
Study included codes for N
% of 
total with 
code lists 
available
  Completed and attempted suicide, 
and self-harm
4 19.1
  Included deaths of undetermined 
intent
7 33.3
  Attempted suicide/self-harm 4 19.1
Table 2 Continued 
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patients with prior diagnoses of dementia from longitu-
dinal analyses.
Of the 17 studies for which the codelists were 
available, 13 reported codes for Alzheimer’s disease 
(81.3%), 13 for vascular dementia (81.3%), 12 for 
frontotemporal dementia (75.0%) and 11 for Lewy 
bodies disease (68.8%) (table 2). Three studies 
reported data for cognitive impairment without 
dementia (17.6%).
Four studies (14.8%) used prescriptions in the iden-
tification of patients with dementia; all four included 
anticholinesterases and dopaminergic agents 
(table 3).
Five studies22–26 involved validation of the list of codes; 
the proportion of cases confirmed varied between 74% 
and 100% (table 4).
The list of Read codes used in the studies is provided 
in online supplementary appendix 4 table 6; the list 
of ICD-10 codes is provided in online supplementary 
appendix 4 table 7.
Fatigue
Six studies had fatigue as the outcome (table 1 and online 
supplementary appendix 3 table 5). All studies consid-
ered codes for diagnoses of fatigue, and five studies 
also described including codes for symptoms of fatigue. 
The list of codes use to identify patients with fatigue was 
provided in three studies (50.0%).
The three studies for which the codelist was available 
included codes for chronic fatigue syndrome, neuras-
thenia and postviral fatigue syndrome (table 2). Fibromy-
algia was included in two studies (66.7%). None of the 
Table 3 Pharmacological categories used in the studies that used drug prescriptions to identify patients with the outcome of 
interest
Outcome No of studies %
Anxiety 12 100.0
  Studies of anxiety that used drugs prescriptions only 0 0.0
  Studies of anxiety that used drugs prescriptions 1 8.3
Diazepam and lorazepam 1 8.3
Depression 42 100.0
  Studies of depression that used drugs prescriptions only 6 14.3
  Studies of depression that used drugs prescriptions 21 50.0
Antidepressants, categories not further specified 15 35.7
Antidepressants, categories further specified 6 14.3
Tricyclic and related antidepressant drugs 3 7.1
Monoamine oxidase inhibitors 3 7.1
Selective serotonin reuptake inhibitors 6 14.3
Other antidepressant drugs 3 7.1
Dementia 27 100.0
  Studies of dementia that used drugs prescriptions only 0 0.0
  Studies of dementia that used drugs prescriptions 4 14.8
Anticholinesterases 4 14.8
Dopaminergic drugs 4 14.8
Pain 8 100.0
  Studies of pain that used drugs prescriptions only 2 25.0
  Studies of pain that used drugs prescriptions 2 25.0
Analgesics, not otherwise specified 2 25.0
Antidepressants 2 25.0
Antiepileptics 2 25.0
Anaesthetics 2 25.0
Sexual dysfunction (male) 6 100.0
  Studies of sexual dysfunction that used drugs prescriptions only 1 16.7
  Studies of sexual dysfunction that used drugs prescriptions 3 50.0
Phosphodiesterase type-5 inhibitors 2 33.3
Prostaglandin analogues and prostamides 1 16.7
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Table 4 Methods and results of the validation of the outcomes reported in the original studies
Outcome and study 
authors Validation method
# case validations 
completed/# case 
validations attempted % of cases confirmed
Anxiety
Martín-Merino et al, 201018 GP questionnaire 135/140 Among pharmacologically 
treated: 73.5%;
Among not pharmacologically 
treated: 89.6%.
Meier et al, 20042 Record review nr/nr nr
Depression
Becker, 2011 Sensitivity analysis with different 
definitions
nr/nr nr
Hagberg, 2016 Record review nr/nr nr
Martín-Merino et al, 201018 GP questionnaire 135/140 89.6%
Meier et al, 20042 Record review nr/nr nr
Yang et al, 200319 Record review 30/nr 83.3%
Anxiety and depression (composite outcome)
John, 2016 Compared 12 EHR algorithms to results 
of the Mental Health Inventory , a 
subscale of SF-36
2799* Between 61% and 76%, 
depending on the algorithm.
Dementia/cognitive impairment
Imfeld et al, 2013 and 
Imfeld et al, 201522 23
GP questionnaire nr/120 Alzheimer’s disease: 79%;
Vascular dementia: 74%.
Dunn et al, 200524 GP asked to confirm diagnosis 50/200 100%
Dunn et al, 200526 GP questionnaire 95/~100 83%
Strom et al, 201525 GP questionnaire 86/100 88.4%
Strom et al, 201525 Review of free text 1047/1048 1.5% patients excluded as 
not having the diagnosis; 
42.4% confirmed as having 
definite memory loss, 36.8% 
possible memory loss, 3.2% 
undetermined and 16.0% 
unknown.
Pain
Hall et al, 20134 GP questionnaire 48/54 56%
Mansfield et al, 201727 EHR data linked to self-reported pain 
status collected by postal questionnaire
1780* 97%
Becker, 2008 GP questionnaire 176/200 86.4%
Self-harm
Thomas et al 201329 Comparison of cases of suicide and 
self-harm identified in CPRD with 
Read codes, with the cases identified 
in CPRD data linked to HES data, and 
published self-harm incidence data.
74236* 68.4%
Suicide (attempted and completed)
Hagberg, 2016 Record review nr/nr nr
Haste, 1998 GP asked to confirm suicides 77% of uncertain 
deaths/nr
82%
Jick, 1995 Record review nr/nr nr
Meier et al, 20042 Record review nr/nr nr
Continued
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studies assessed the validity of the list of the codes. The 
list of Read codes used in the studies of fatigue is available 
in online supplementary appendix 4 table 8.
Pain
Pain was the outcome in eight studies (table 1 and online 
supplementary appendix 3 table 6). The list of codes 
was available for four of the eight studies. Of these four 
studies, three looked at pain by body site (ie, chest, abdom-
inal, musculoskeletal pain), one study studied widespread 
body pain (table 2). Two studies included drugs in the 
identification of patients with pain; all considered antiepi-
leptics (in the absence of codes for an epilepsy diagnosis), 
anaesthetics, antidepressants and analgesics (table 3).
Three studies validated the list of patients selected with 
the codelist (table 4). The proportion of cases confirmed 
varied between 56% and 86.4%. One study compared 
pain recorded in the EHR with pain reported in a survey; 
in 97% of the self-reported cases of pain, there was an 
entry in the EHR.27
Online supplementary appendix 4 table 9 provides the 
list of codes used in the original studies.
sexual dysfunction
Six studies had sexual dysfunction as an outcome, all 
of which focused on male sexual dysfunction (table 1, 
online supplementary appendix 3 table 7). Three studies 
provided codelists (50.0%). Of these, all included codes 
for erectile dysfunction and one study included codes for 
other male sexual dysfunctions (table 2). Three studies 
included considered the prescription of drugs sufficient 
to ascertain the outcome; two studies considered phos-
phodiesterase type-5 inhibitors (table 3). No study vali-
dated the list of codes used. The list of Read codes used in 
the original studies is available in online supplementary 
appendix 4 table 10.
sleep disorders
Two studies were eligible for sleep disorders (table 1, 
online supplementary appendix 3 table 8); the two studies 
included diagnoses of insomnia, and one included hyper-
somnia as well (50%) (table 2). The list of codes was avail-
able for one study. No validation was reported. Online 
supplementary appendix 4 table 11 provides the list of 
Read codes used in the original study.
Fatal and non-fatal self-harm
Forty-one studies had outcomes related to fatal and 
non-fatal self-harm (table 1 and online supplementary 
appendix 3 table 9). The list of codes used to define the 
outcomes was available for 21 studies (51.2%); 9 studies 
reported using ICD-10 codes.
Of the 21 studies for which the codelist was available, 
17 studies (80.9%) included completed suicide, while 
4 studies focused on attempted suicide only (19.1%). 
Of the 17 studies including completed suicide as an 
outcome, eight reported only completed suicides, six 
considered completed and attempted suicides and four 
included complete and attempted suicide, as well as self-
harm (table 2). All studies where outcomes were identi-
fied using primary care data linked to ONS mortality data 
(gold standard) considered deaths recorded as of unde-
termined intent in the definition of suicide.
Nine studies involved some method of validation of 
the list of cases identified via code search (table 4). Four 
studies referred to have revised the clinical record of the 
patient to determine the final outcome and two studies 
asked the GPs to confirm the events. The proportion of 
Outcome and study 
authors Validation method
# case validations 
completed/# case 
validations attempted % of cases confirmed
Schuerch, 2016 Outcomes identified in CPRD were 
compared with those identified in CPRD 
linked to HES and ONS data.
nr/nr Compared with CPRD data, the 
frequency of the outcomes in 
linked data was approximately 
three times higher.
Yang et al, 200319 Record review 30/nr 83.3%
Suicide (completed)
Arana, 2010 GP questionnaire and record review nr/132 97%
Arana, 2010 GP questionnaire and record review nr/86 87%
Hall, 200928 GP questionnaire and record review 33/33 21.2%
Thomas et al, 201329 Comparison of cases of suicide and 
self-harm identified in CPRD with 
Read codes, with the cases identified 
in CPRD data linked to ONS mortality 
data, and national suicide rates.
1767* 59.7% for men;
46.0% for women.
*Validation attempted and completed for all patients identified in electronic health records database.
CPRD, Clinical Practice Research Datalink; EHR, electronic health record; GP, general practitioner; HES, Hospital Episode Statistics; nr, not 
reported; ONS, Office for National Statistics; SF-36, 36-item Short Form Health Survey. 
Table 4 Continued 
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cases confirmed varied between 21.2% and 97%. Hall28 
assessed the validity of cause of death recording in the 
THIN primary care database through search of the free 
text and death certificate review; the underlying cause of 
death registered in the death certificate was listed as the 
cause of death in the EHR in 70% of the cases. Thomas et 
al29 compared the ascertainment of cases of suicide and 
self-harm using Read codes in CPRD, with those ascer-
tained when data from HES and ONS mortality data were 
available. 26.1% of the cases of suicide identified in the 
ONS mortality data were registered in the CPRD primary 
care database. HES was considered the gold standard for 
self-harm; 68.4% of the cases of self-harm in HES were 
identified as such in CPRD.
Online supplementary appendix 4 table 12 provides the 
list of Read codes used to identify outcomes of fatal and 
non-fatal self-harm in primary care data; online supple-
mentary appendix 4 table 13 includes the lists of ICD-10 
codes using in studies of linked data.
DIsCussIOn
results overview
This review summarised the definitions and combi-
nations of codes used to identify outcomes of anxiety, 
depression, dementia and cognitive impairment, fatigue, 
pain, male sexual dysfunction, sleep disorder and self-in-
jurious behaviour in primary care databases of patients 
in the UK. The list of codes used in the original studies 
was obtained for approximately half of the papers; the 
lack of detailed information on the definition of the 
outcomes in most studies raises important questions as 
to whether studies can be replicated by others. In the 
studies where the codelist was available, for all outcomes, 
there was substantial heterogeneity in the type of codes 
included (eg, diagnoses and symptoms) and drugs 
selected to identify outcomes; for the remaining studies, 
the details provided in the original publications suggest a 
similar pattern. We also noted considerable variability in 
the clinical definition of some outcomes (eg, inclusion/
exclusion of bipolar disorders in studies of depression). 
Validation of codes used to identify these outcomes was 
rarely carried out; where done, positive predictive values 
of case definitions were variable but mostly above 80%. To 
overcome these issues in the current context of limited 
number of studies with validation efforts, it is impera-
tive that researchers develop, validate and make publicly 
available code lists for these outcomes.
strengths and limitations
This review is based on an extensive search of the studies 
involving EHRs in the UK. Errors in study selection and 
data extraction were minimised by the independent assess-
ment of the studies by two investigators. We contacted the 
authors of all original studies where the list of codes had 
not been provided in the original publication to seek this 
information; this largely increased the number of studies 
for which lists of codes were available, and contributed to 
a more detailed characterisation of the combination of 
codes used to define mental health outcomes in primary 
care databases of EHR in the UK.
However, this review has limitations. Some relevant 
studies may have been missed due to imperfect search 
terms, as there is no Medical Subject Headings (MeSH) 
term for the primary care databases, and studies could be 
potentially missed if the keywords did not appear in the 
title and abstract, or due to inaccurate indexing in the 
publications database. We attempted to minimise the risk 
of missing potential eligible studies by using broad search 
terms incorporating both indexing terms and keywords, 
two databases with different indexing systems, and an 
additional manual check of the eligible studies and list of 
bibliographical references from the main EHR databases. 
We only considered studies where mental health or QoL 
variables were the outcomes of interest, limiting gener-
alisability to other contexts. For example, we excluded 
studies where these variables were covariates because we 
expected that detailed information about covariate defi-
nitions would rarely be available. We also excluded studies 
where the mental health or QoL variable was used to 
define the patient population (eg, a study of risk of stroke 
in depressed patients), on the basis that decisions about 
how to define cases may have had quite different motiva-
tions, compared with studies where the condition was the 
outcome of the study, making case definitions difficult to 
meaningfully compare. We included studies that explicitly 
referred to using prescription data as a proxy for the defi-
nition of the condition (eg, treated depression assessed 
by proxy of antidepressant intake), but we acknowledge 
that it was not always clear to decide whether treatment 
of the condition was being used to define the condition. 
This could have resulted in a few studies erroneously 
excluded, even though this should have been minimised 
by the duplication of the search and study selection 
process by two researchers working independently, with 
discussion of all discordant results. It is unclear if the list 
of codes that could not be obtained differ in any system-
atic way to the ones obtained. Some authors expressed 
concerns over intellectual property when sharing the list 
of codes, and this may have been a bigger concern among 
those who put a lot of time and thought into their codel-
ists; on the other hand, authors who have concerns about 
the quality of their codelist may have been less willing to 
share them. Lastly, we summarised the types of codes used 
to define the outcome based on what was stated in orig-
inal studies’ methods sections (because code lists were 
not available for all studies), but this may have been inac-
curate, for example, some studies that reported in their 
methods only including diagnosis codes then provided 
code lists that appeared to also contain symptom codes.
Availability of the list of codes
The list of codes was provided in the original publica-
tions for just over a quarter of the studies. Contacting 
the authors resulted in codelists being made available 
for approximately half of the studies. For the remaining 
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studies, the authors either could not be contacted (eg, 
moved institutions, retired) or could not locate the 
relevant codelist (including for some studies where the 
paper had stated that the codelist would be available on 
request). Provision of codelists within the publication 
or in a web repository would eliminate the difficulties 
of authors having to be contacted and archived codel-
ists retrieved. Most journals currently accept codelists in 
online supplementary appendices. Codelists were hardly 
ever obtained for older studies, especially those published 
before 2000, when email addresses were not routinely 
included in the details of the corresponding authors. We 
searched for alternative contacts in these cases, but not 
always successfully.
Variability in the definition of cases and codelists
Anxiety and depression
Anxiety was often defined with diagnostic and symptoms 
codes, and in a few studies by the prescription of anxio-
lytics and hypnotics. Even though the sensitivity of symp-
toms codes for anxiety is expected to be high, the positive 
predictive value is unknown. Anxiolytics may also result 
in misclassification of the outcomes, as they are currently 
discouraged as first line of treatment for anxiety12 and 
are often prescribed for management of other conditions 
such as insomnia. No study considered antidepressants in 
the definition of anxiety even though these are currently 
used to manage anxiety12; this may have resulted in cases 
of anxiety treated with antidepressants, and where no 
Read code was available, being missed.
The inclusion/exclusion of codes for symptoms may 
have a larger impact in the definition of depression, as 
it has been shown that GPs switched from diagnostic to 
symptoms codes after the introduction of performance 
indicators in the GP contract Quality and Outcomes 
Framework in 200611 and under claims that depression 
was being overdiagnosed.30 31 Codelists solely relying on 
Read codes for diagnosis of depression are, therefore, 
likely to have low sensitivity, but the impact of including/
excluding a specific code will be variable, depending on 
how often that code is used by GPs at the point of providing 
care. In a few studies, depression was defined by proxy of 
antidepressant prescribing, alone or in combination with 
Read codes for symptoms/diagnosis. Considering anti-
depressant prescribing in the definition of depression 
has several issues. Certain types of antidepressants are 
currently used as first line of treatment for other condi-
tions, such as pain and anxiety, and the studies relying 
solely on this information will be affected by misclassifica-
tion of the outcome; some studies took this into account 
by excluding low dose tricyclic antidepressants, usually 
prescribed for pain, from their list of codes used to define 
depression.32–34 Among the studies that did include anti-
depressants in their definition, there was heterogeneity in 
the group of antidepressants included, with some studies 
selecting only a few specific drugs commonly used for the 
treatment of depression. Studies defining depression by 
proxy of antidepressant prescribing only are likely also 
to be affected by changes in the behaviour of antide-
pressant prescribing. In 2004, the National Institute for 
Health and Care Excellence (NICE) issued guidelines 
discouraging antidepressants for mild depression,35 and 
in 2006 a performance indicator in the UK GP Quality 
and Outcomes Framework pay for performance was 
introduced for depression severity assessed with validated 
symptoms questionnaires.36 Following this measure, the 
proportion of new cases of pharmacologically treated 
depression decreased (from 73% in 2003 to 61% in 
201237), but the proportion of recurrent episodes phar-
macologically treated increased from 74.3% to 77.8%.37 
Treatment duration times with antidepressants also 
increased over time38; this may affect the number of new 
episodes of depression identified in the studies. In several 
studies, the authors chose to report separate results for 
antidepressant prescribing, without using this informa-
tion to ascertain the outcome of depression39 40; this may 
partially be due to the difficulties of ascertaining the indi-
cations for which antidepressants were prescribed. John 
et al explored the indications of antidepressants; more 
than half of the new antidepressant prescriptions were for 
depression, with increasing but low incidence of prescrip-
tions for pain and anxiety, but the authors could not iden-
tify the indication for antidepressants in 17% of the new 
prescriptions.41
Regardless of the type of codes included, authors will 
need to often choose the inclusion/exclusion of codes 
relating to the clinical profile of the patients. This may 
have a particular impact for conditions that are highly 
comorbid. For example, the code for ‘mixed anxiety 
and depression’ was sometimes used in the definition of 
anxiety and in the definition of depression; anxiety and 
depression are highly comorbid and the inclusion/exclu-
sion of these patients may have an impact on the results. 
In addition, for depression, the inclusion of codes related 
to depression in the context of bipolar disease, dementia 
and schizophrenia may raise issues as to whether it 
represents a primary depressive episode.
Part of the heterogeneity in the list of codes used to iden-
tify these outcomes may be explained by the complexity of 
these conditions and by the purpose for which these data 
are collected. Electronic healthcare data are primarily 
collected to provide patients with treatment, and distinc-
tions between diagnosis and symptoms may have less 
weight at the point of care than when researchers aim 
to define these conditions using data routinely collected.
Fatal and non-fatal self-harm
Routinely collected primary care data were shown to have 
low sensitivity to detect cases of suicide.29 Thus, record 
linkage to ONS mortality data is of interest; this has the 
advantage of including causes of death other than suicide. 
Ascertainment of the cause of death is not always straight-
forward when the death is non-natural, and several studies 
have included cases of accidents and open verdicts in 
their case definition. Open verdicts have been shown to 
include many similarities with suicides, and several are 
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later registered as suicides; these are recommended to be 
included in studies of suicide.42 Studies varied on whether 
cases of self-harm without suicidal ideation were included 
(eg, Rubino et al reviewed free text to exclude those who 
did not seem to have attempted suicide43). For self-harm, 
linkage to HES data will allow for more cases to be iden-
tified,29 even though authors must consider the balance 
between reduction of sample size and ascertainment of 
the outcome, as linkage is only available for a subset of 
patients.
Pain
The aetiology and location of pain in the studies involved 
in this review varied due to our broad inclusion criteria. 
When pharmacological treatment was included in the 
definition of pain, this was most often done with prescrip-
tions of antidepressants and antiepileptics. Antidepres-
sants such as first-generation tricyclic antidepressants 
have been used for over 30 years to manage neuropathic 
pain (eg, amitriptyline, doxepin, clomipramine and 
dosulepin).44 Antiepileptic drugs reduce neuronal excit-
ability and alleviate pain through several mechanisms.44
Other outcomes
We considered cognitive dysfunction as a composite 
outcome including studies from mild to severe impair-
ments such as those in dementia; between 10% and 
20% of the patients with mild cognitive impairment are 
expected to convert to dementia.45 46 Fewer studies had 
fatigue, sexual dysfunction and sleep disorders as the 
outcome, and no study was eligible for female sexual 
dysfunction. The definition of these outcomes varied little 
across the studies but the small numbers preclude firm 
conclusions. It has been reported that chronic fatigue 
increased prior to 2001,3 but decreased between 2001 
and 2013,47 possibly due to the introduction of diagnostic 
criteria from NICE48; in the same period, increases were 
noted in the diagnoses of fibromyalgia.47 This may reflect 
the complexity of diagnosing fatigue, which is done by 
exclusion of other causes only.48
Validation
Outcomes identified in EHRs may lack of validity: a person 
meeting the operational definition for the outcome based 
on specific codes may not have the diagnosis or vice versa. 
Only a small number of studies assessed validity in their 
studies, and this was almost always about assessing posi-
tive predictive value of the case definition, with sensitivity 
and specificity rarely explored. Of these, some studies 
only stated that validation had been carried out, but did 
not report the results, which makes the performance of 
the case definition unclear. However, the studies that 
reported results tended to show a high proportion of cases 
confirmed by their primary care physician or by further 
investigations (ie, a high positive predictive value). This 
is in accordance with the results of two systematic reviews 
that assessed the validity of the diagnostic coding within 
the CPRD primary care database.8 9 Studies in which 
identified cases were validated by the GP did not usually 
specify how this validation was done—that is, whether the 
GPs confirmed cases by consulting the EHR, referring 
to additional information, relying on memory or using 
other methods. If GPs simply checked the same EHR used 
to identify the case in the first place, resulting estimates 
of positive predictive value would be expected to be high, 
but may be misleadingly optimistic.
Implications
Mental health and QoL-related outcomes are difficult 
to identify in EHR databases; and thus, extra care needs 
to be used when defining these outcomes. The use of 
a particular code can vary between GP practices; for 
example, a study on the interpractice use of Read codes 
for diabetes showed that the most generic code was used 
in 14%–98% of the patients with diabetes in the prac-
tices.49 GPs can derive Read codes for their practice; this 
may raise issues with new codes being added over time,50 
and codelists that need to be updated. It is important that 
authors clearly document the process of selection of the 
codes, so that these are available with clear rationale if 
needed.5 Repositories of lists of codes allow researchers 
to access codelists easily. However, these repositories also 
need funding to be maintained, which limits their stability 
and consequently their use. Some studies of depression 
and dementia referred to using the Read codes recom-
mended by the Quality and Outcomes Framework36; 
these are likely to be highly specific. It is also important 
to better understand the patterns of recording of some of 
these conditions, as changes in the patterns of use of the 
codes may have impact in the list of codes chosen. The 
inclusion of codes for symptoms and prescriptions must 
consider what is known about the use of codes by GPs at 
the point of patient providing care, as data recording in 
this setting is primarily intended to support clinical care. 
Future works are needed to understand how GPs concep-
tualise mental health problems, as these are expected 
to have less stringent definitions than psychiatrists, and 
this could provide insights into more meaningful case 
definitions.
Validation of the outcomes appears to be essential to 
understand the validity of case definitions. A balance 
between sensitivity and specificity may be considered 
depending on the aim of the study5; for depression, for 
example, the inclusion of terms such as ‘low mood’ may 
increase sensitivity, at the expense of decreased speci-
ficity, as some individuals who would not fit more strin-
gent criteria for a diagnosis will be incorrectly classified 
as depressed.5 A particular challenge with validation of 
primary care-based mental health outcomes is quantifying 
false negatives, which requires linkage to a high-quality 
external source of information, to identify cases that may 
have been ‘missed’ in primary care records. The Mental 
Health Dataset, which includes individual patient records 
of adults seeking mental health services in secondary care 
and has recently been made available for linkage with 
CPRD primary care databases, represents an opportunity 
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to assess the proportion of false negatives identified with 
the code lists, at least for more severe outcomes. Until 
then, sensitivity analysis using different lists of codes 
should be done, so that results can be compared and the 
impact of using different code lists evaluated. The conse-
quences of underascertaining mental health outcomes 
are likely to depend on study design; in a cohort design 
this will not generally result in biased relative risks, 
whereas in a case–control context, a bias towards the null 
is likely. Studies might consider to use internal validation 
strategies, by assessing the proportion of patients referred 
for treatment or prescribed a relevant pharmacological 
agent.
Primary care databases of EHRs have made important 
contributions to medicine worldwide, particularly in 
the fields of infectious, respiratory and cardiovascular 
diseases. The burden of mental disorders in high-in-
come countries has increased substantially in the last 
decades,51 and more research is needed to be better 
understand these conditions. Primary care databases of 
EHRs have potential to make huge contributions to this 
area but, for this to happen, we need coordinated efforts 
across funding and research organisations to improve 
data quality. For example, if scientific journals make a 
requirement of having publicly available lists of codes, 
this would likely encourage researchers to spend more 
time defining the outcomes and potentially seek funding 
for validation studies, which in turn could increase the 
awareness of funding institutions for the importance of 
assessing data quality in projects using these data. In the 
meantime, transparency in the list of codes used to define 
these outcomes and reporting of sensitivity analysis with 
different lists of codes are key.
Despite the difficulties of assessing each separate 
outcome, we must take into account that mental health 
disorder symptoms often overlap, and is difficult to disen-
tangle what is attributable to each condition. Lastly, these 
conditions have a long period of exposure to medication 
after symptoms have disappeared, besides a high proba-
bility of relapse and recurrence,52 which may raise issues 
on whether the condition is incident or prevalent.
COnClusIOns
Detailed information about codes used to identify 
outcomes of anxiety, depression, fatigue, cognitive 
dysfunction, sexual dysfunction, pain, sleep disorders, 
and fatal and non-fatal self-harm in studies using EHRs 
from primary care databases in the UK was unavailable 
for around half of studies of these outcomes. Where 
available, there was substantial heterogeneity in the list 
of codes used to ascertain cases. Most studies did not vali-
date case definitions, though when this was done, posi-
tive predictive values were generally high. This review 
focused on common mental health disorders and QoL 
outcomes, but our conclusions are likely to be generalis-
able to other mental health outcomes. Caution is needed 
when interpreting and comparing results between 
studies, as heterogeneity in case definitions may be large. 
Future studies should fully report outcomes definitions, 
use sensitivity analysis to mitigate uncertainties about 
the impact of the case definition on studies’ reported 
outcomes, and seek to validate the list of codes used to 
identify these outcomes.
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